Today's Sponsored Feature is part of your subscription to the daily AAP SmartBrief. This feature, produced by SmartBrief and a select group of sponsors, highlights issues, products and services of interest to pediatricians and other child health professionals. It also allows for continued free delivery of AAP SmartBrief. Thank you for your interest.

- The AAP SmartBrief Team

New comprehensive brain tumor program

With the creation of a comprehensive pediatric brain tumor program, Children's Mercy has taken another step toward cementing its status as one of the nation's premier pediatric oncology centers. "One of the goals is to have a clinical trial for every major type of pediatric brain tumor; for new diagnoses as well as for relapse," says the program's director, Dr. Kevin Ginn, MD.

Read the full article

Learn more about the oncology program at Children's Mercy
Leading a large antibody therapy trial for AML

One of the difficulties in treating acute myeloid leukemia (AML) is relapse. But Children's Mercy researchers are leading efforts to find new and novel methods for targeting leukemia cells with chemotherapy that could introduce new or more intense agents for more effective cures.

Read the full article

Learn more about the oncology program at Children's Mercy
Located in Kansas City, Mo., Children's Mercy Hospitals and Clinics is one of the country's premier free-standing, independent pediatric medical centers. With a faculty of more than 400 pediatric subspecialists, we are consistently ranked among the leading children's hospitals in the nation. Likewise, we were the first hospital in Missouri or Kansas to receive Magnet recognition by the American Nurses Credentialing Center for excellence in nursing services.

The internationally recognized physicians and scientists at Children's Mercy Hospitals and Clinics have quietly turned Kansas City into a major hub for pediatric oncology research and treatment. With 21 board-certified/eligible physicians and 23 advanced practice nurses on staff who see 2,000 children per year, the Division of Hematology/Oncology at Children's Mercy is one of the larger childhood cancer centers in the country. And with an overall survival rate of 83 percent, we're at or above the national average for nearly every type of cancer we treat.
Advancing early phase drug trials

The Experimental Therapeutics in Pediatric Cancer Program is gaining recognition as a leader in pediatric cancer pharmacology. The program has its own investigator-initiated trials and is working with several national consortia, including POETIC, NMTRC and TACL.

Read the full article
  • Report finds continued decline of cancer deaths in U.S.
    Cancer mortality rates among men, women and children dropped every year from 2000 to 2009, continuing the downward trend that started in the 1990s, a report in the Journal of the National Cancer Institute showed. New cancer diagnoses dropped in men and remained unchanged in women, but pediatric cancer diagnoses rose by 0.6% during the study period. WebMD (1/7), HealthDay News (1/7)
  • FDA advisers discuss pediatric cancer meds
    A panel of FDA advisers is meeting to discuss testing four drugs with potential to treat childhood cancers. Relatively few children are affected by cancer, making robust clinical trial design difficult. The FDA requires drugmakers to study their products in children if that population is prone to the target disease, and new legislation taking effect in January will require those studies even earlier. Bloomberg (12/4)
  • Fertility is rarely discussed with young cancer patients
    More and more evidence suggests that not enough young cancer patients are told about the potential impact that therapy could have on their fertility, and fewer still receive fertility counseling or undergo fertility preservation. The American Society of Clinical Oncology plans to release updated guidelines in the next year that more forcefully urge oncologists to discuss fertility issues with patients before treatment begins. The Huffington Post (11/29)
  • Computational genomics drives personalized cancer care
    Software engineers are emerging as key players in the drive to translate massive amounts of genomic data into drugs that target specific genetic mutations. Using processing units that each have about the same amount of computing power as the average personal computer, computational biologists are developing algorithms to identify recurring genetic patterns in tumors. Drugmakers will increasingly work with software developers, such as Microsoft, to create new algorithms, methodologies and even therapies, said Les Jordan, chief technology strategist at Microsoft's Life Sciences unit. Reuters (11/1)
What is this?A Sponsored Feature is an advertorial that includes valuable content provided by the sponsor and editorial materials from SmartBrief's archives. This Sponsored Feature does not represent an endorsement by the AAP or SmartBrief, Inc. of the products and services offered. If you unsubscribe from this Sponsored Feature, you will not be unsubscribing from all other editions of the AAP SmartBrief.
Subscriber Tools:
Sign up for AAP SmartBrief | Send Feedback | Email this brief | Unsubscribe from AAP SmartBrief Sponsored Features
Advertising with SmartBrief:Sales Account Director Aaron Kern 202-407-7866
Mailing Address:SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2013 SmartBrief, Inc.®  Legal Information.